首页 / 院系成果 / 成果详情页

Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer 期刊论文

编号：

1526B147967CB5F8AA693017101B2609
作者：

Ni, Jun#^[1]Huang, Miao#^[2]Zhang, Li*^[1]Wu, Nan*^[2]Bai, ChunXue^[3];Chen, LiangAn^[4];Liang, Jun^[5];Liu, Qian^[6];Wang, Jie^[7];Wu, YiLong^[8];Zhang, FengChun^[1];Zhang, ShuYang^[1];Chen, Chun^[9];Chen, Jun^[10];Fang, WenTao^[11];Gao, ShuGeng^[7];Hu, Jian^[12];Jiang, Tao^[13];Li, ShanQing^[1];Li, HeCheng^[14];Liao, YongDe^[15];Liu, Yang^[4];Liu, DeRuo^[16];Liu, HongXu^[17];Liu, JianYang^[18];Liu, LunXu^[19];Wang, MengZhao^[1];Wang, ChangLi(王长利)^[20]Yang, Fan^[21];Yang, Yue^[2];Zhang, LanJun^[22];Zhi, XiuYi^[23];Zhong, WenZhao^[8];Guan, YuZhou^[1];Guo, XiaoXiao^[1];He, ChunXia^[1];Li, ShaoLei^[2];Li, Yue^[1];Liang, NaiXin^[1];Lu, FangLiang^[2];Lv, Chao^[2];Lv, Wei^[1];Si, XiaoYan^[1];Tan, FengWei^[7];Wang, HanPing^[1];Wang, JiangShan^[1];Yan, Shi^[2];Yang, HuaXia^[1];Zhu, HuiJuan^[1];Zhuang, JunLing^[1];Zhuo, MingLei^[2];
语种：

英文
期刊：

THORACIC CANCER ISSN：1759-7706 2021 年 12 卷 9 期 (1469 - 1488) ; MAY
收录：
关键词：

clinical recommendation irAE non&amp #8208 small cell lung cancer perioperative immunotherapy
摘要：

Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, in patients with lung cancer has increased our expectations for the success of these therapeutics as neoadjuvant immunotherapy. Neoadjuvant therapy is widely used in patients with resectable stage IIIA NSCLC and can reduce primary tumor and lymph node stage, improve the complete resection rate, and eliminate microsatellite foci; however, complete pathological response is rare. Moreover, because the clinical benefit of neoadjuvant therapy is not obvious and may complicate surgery, it has not yet entered the mainstream of clinical treatment. Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancellation of surgery, additional illness, and even death, and have therefore attracted much attention. In this article, we draw on several sources of information, including (i) guidelines on adverse reactions related to immune checkpoint inhibitors, (ii) published data from large-scale clinical studies in thoracic surgery, and (iii) practical experience and published cases, to provide clinical recommendations on adverse events in NSCLC patients induced by perioperative immunotherapy.
推荐引用方式
GB/T 7714：

Ni Jun,Huang Miao,Zhang Li, et al. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer [J].THORACIC CANCER,2021,12(9):1469-1488.
APA：

Ni Jun,Huang Miao,Zhang Li,Wu Nan,&Zhuo Ming-Lei.(2021).Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer .THORACIC CANCER,12(9):1469-1488.
MLA：

Ni Jun, et al. "Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer" .THORACIC CANCER 12,9(2021):1469-1488.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：45  下载次数：0

分享到：

浏览次数：45

下载次数：0

打印次数：0